Beverly Lu

Beverly Lu is the Portfolio Manager at Emerson Collective, an oncology-focused fund. Dr. Lu specializes in company creation and early-stage investments of breakthrough technologies across therapeutics, diagnostics, and tools & reagents in Oncology. She brings 15+ years of life science experience across R&D, business development, corporate strategy and operations, and venture investment. Prior to Emerson Collective, Dr. Lu was Strategy & Operations Director at Amgen US, responsible for driving and executing key decisions for 50% of Amgen’s business. At Amgen, Dr. Lu led large cross-functional initiatives that transformed business performance, successfully commercialized new products, and innovated customer engagement models. Before Amgen, she spent 4 years at McKinsey & Company helping numerous pharmaceutical companies solve challenges including R&D strategy and operations, business development, and commercialization strategies. Beverly has deep scientific expertise in immuno-oncology and therapeutic protein engineering. She completed her undergraduate education in Chemical Biology at UC Berkeley with the highest honor, Ph.D. research in Chemistry at CalTech, and immuno-oncology postdoctoral research at Harvard University.